Navigation Links
Watson Announces Silodosin NDA Accepted for Filing by FDA for the Treatment of Benign Prostatic Hyperplasia
Date:2/12/2008

CORONA, Calif., Feb. 12 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today announced that its New Drug Application (NDA) for silodosin, a novel alpha(1)- adrenoreceptor antagonist, has been accepted for filing by the U.S. Food and Drug Administration (FDA). Watson is seeking marketing approval of silodosin from the FDA for the treatment of the signs and symptoms associated with benign prostatic hyperplasia (BPH), or enlarged prostate. Watson anticipates that the FDA will take action on its application in the fourth quarter 2008.

Silodosin was designed to decrease urinary resistance and improve dysuria (difficulty or pain in urination) associated with BPH. In clinical trials, silodosin demonstrated a very low level of the most highly-reported cardiovascular and blood pressure-related side effects associated with existing BPH treatments, including dizziness and first-dose syncope (fainting).

"This filing highlights Watson's capabilities in new drug development and our commitment to this product, providing solutions to the millions of men with BPH symptoms," said Paul Bisaro, Watson's President and Chief Executive Officer. "Watson is expanding the portfolio it offers to urologists and their patients, focusing on symptom management that makes a big difference in their day-to-day lives."

Watson submitted the filing for silodosin with data from two Phase 3 multi-center (88 sites), randomized, double-blind, placebo-controlled trials that evaluated a total of 923 patients with signs and symptoms of BPH for 12 weeks. The trials demonstrated that a once daily 8mg dose of silodosin given for 12 weeks provided significant relief of BPH symptoms, compared with place
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Watson Announces Positive Results From Its Pivotal Study of Oxybutynin Topical Gel for the Treatment of Overactive Bladder
2. Watson Launches Generic Biaxin(R) XL
3. Micromet Announces the Publication of BiTE Antibody Review in Drugs of the Future
4. Pharmacyclics Announces Data and Publication Characterizing Highly-Selective HDAC Inhibitor
5. Emisphere Technologies Announces Positive Results From Animal Studies on Oral B12 Using eligen(R) Technology
6. PTC Therapeutics Announces Publication of Preclinical Data in PNAS
7. IDM Pharma Announces Phase 3 Mifamurtide (L-MTP-PE) Study Demonstrating Improved Survival Published in the Journal of Clinical Oncology
8. TargeGen Announces Initiation of Clinical Trial of JAK2 Inhibitor TG101348 in Myeloproliferative Disease Patients
9. Inverseon Announces Positive Phase IIa Asthma Study
10. Genomic Health Announces Identification of Genes Associated With Colon Cancer Recurrence Across Multiple Studies
11. N30 Pharma Announces Successful Initiation of Human Studies With N30-201
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... ST. LOUIS , Oct. 1, 2014  Express ... its two nationally available 2015 Express Scripts Medicare ® ... retail pharmacy network featuring Walgreens (NYSE: WAG ... obtain more value, choice and clinical support  for their ... the Express Scripts Medicare Value or ...
(Date:10/1/2014)... , Oct. 1, 2014   Royal Philips ... today announced its eCareCoordinator and eCareCompanion telehealth applications ... and Drug Administration (FDA). A part of Philips ... , eCareCoordinator and eCareCompanion are focused on patient ... clinical applications to be available through the cloud-based ...
(Date:10/1/2014)... 2014 Ardelyx, Inc. (NASDAQ: ... focused on cardio-renal, gastrointestinal and metabolic diseases, ... patient Phase 2b clinical trial evaluating tenapanor ... (IBS-C).  Results from this study demonstrated statistically ... symptoms for tenapanor-treated patients compared to patients ...
Breaking Medicine Technology:Express Scripts Collaborates with Walgreens to Create Value-Driven Medicare Prescription Drug Plan Pharmacy Network 2Express Scripts Collaborates with Walgreens to Create Value-Driven Medicare Prescription Drug Plan Pharmacy Network 3Express Scripts Collaborates with Walgreens to Create Value-Driven Medicare Prescription Drug Plan Pharmacy Network 4Philips Secures 510(k) Clearance to Market the First Clinical Applications for its new Digital Health Platform 2Philips Secures 510(k) Clearance to Market the First Clinical Applications for its new Digital Health Platform 3Philips Secures 510(k) Clearance to Market the First Clinical Applications for its new Digital Health Platform 4Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 2Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 3Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 4Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 5Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 6
... MASI ) announced today that it will release first ... the market closes on May 2, 2012. The conference call to ... ET) and will be hosted by Joe Kiani, Chairman and Chief ... Chief Financial Officer. A live webcast of the conference ...
... 2012 Financial executives in the medical device manufacturing ... burden of its related compliance costs will have a ... a survey conducted by KPMG LLP, the audit, tax ... companies are already contemplating actions such as price increases ...
Cached Medicine Technology:Masimo to Report First Quarter 2012 Financial Results after Market Close on May 2 2Masimo to Report First Quarter 2012 Financial Results after Market Close on May 2 3KPMG Survey: Medical Device Execs Say New Excise Tax Will Hit Their Company Bottom Lines Hard 2KPMG Survey: Medical Device Execs Say New Excise Tax Will Hit Their Company Bottom Lines Hard 3
(Date:10/1/2014)... brain of a rat and a robot could revolutionise ... leading robotics researcher. , Dr Michael Milford from ... uses new computer algorithms to enable robots to navigate ... is a very Frankenstein type of project," Dr Milford ... together because we,re taking the eyes of a human ...
(Date:10/1/2014)... Patients with increased inflammation, including those receiving cytokines ... of depression. For example, a 6-month treatment course ... infection causes depression in approximately 30% of patients. ... as fish oil, have a long list of ... disease and reducing triglyceride levels. These nutritional compounds ...
(Date:10/1/2014)... suggests the adage that encourages people to keep their ... it comes to exercise. When walking, staying focused on ... it appear shorter and help people walk there faster, ... technique to walking while looking around the environment naturally, ... exercise. , "People are less interested in exercise if ...
(Date:10/1/2014)... Marriagelifeinsurance.com has released a new blog post explaining how ... Senior citizens can purchase a joint life insurance policy ... joint policy is cheaper, but will only pay benefits ... insurance can be used to cover important funeral expenses. ... as the application process is simple and straightforward. ...
(Date:10/1/2014)... Chino Hills, CA (PRWEB) October 01, 2014 ... the internationally-franchised Fit Body Boot Camp fitness boot camps, ... selling personal training , with sold out business ... a stint as marketing consultant to a recent Spike ... looming, Keuilian says that now is the time for ...
Breaking Medicine News(10 mins):Health News:Robot researcher combines nature to nurture 'superhuman' navigation 2Health News:Omega-3 fatty acids may prevent some forms of depression 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 3Health News:Elderly Life Insurance - Find Life Insurance for Retired Couples! 2Health News:Bedros Keuilian Shares Tips on Selling Personal Training for the Holidays 2Health News:Bedros Keuilian Shares Tips on Selling Personal Training for the Holidays 3
... A clinical trial in Cambodia has found it possible ... very weak immune systems and newly diagnosed tuberculosis (TB) ... treatment, rather than waiting eight weeks, as has been ... Institute of Allergy and Infectious Diseases (NIAID), part of ...
... July 22 Adult circumcision has been proposed as a ... study by the University of Pittsburgh Graduate School of ... suggests it would have a very small effect on reducing ... thought to reduce the risk of HIV transmission by removing ...
... insulin resistance and the action of diabetes drugs such ... improved medications that are more selective and safer, say ... Institute. "Our findings strongly suggest that good and ... designing second-generation drugs that focus on the newly uncovered ...
... College Park, MD (July 20, 2010) -- Eighty years ago, ... of metabolism, but the idea went out of vogue. Now, ... cancer and other common diseases. Metabolism is a highly connected ... pathways. Such parallelism can mask how genes are linked ...
... Cancer surgery wreaks havoc on a body,s immune system and ... of those who undergo surgery for tumor removal experience a ... of the body. A new clinical approach being ... the key to making cancer operations more successful. Prof. Shamgar ...
... group of patients at one of the nation,s largest ... who have previously refused colorectal cancer screening, are willing ... but not willing to pay for the exam themselves ... in the August issue of the American Journal ...
Cached Medicine News:Health News:NIH-funded study finds early HAART during TB treatment boosts survival rate in co-infected people 2Health News:Scientists find unsuspected molecular link between obesity and insulin resistance 2Health News:Scientists find unsuspected molecular link between obesity and insulin resistance 3Health News:A new drug treatment to close the window on colon cancer 2Health News:Lack of insurance coverage remains obstacle to wider colorectal cancer screening with CT colonography 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: